Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Sep 5, 2021

SEC Form 4	FORM 4					UNITED STATES SECURITIES AND EXCHANGE COMMISSION
						Washington, D.C. 20549										OMB APPROVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).						STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number:	Estimated average burden hours per response:	3235-0287 0.5
1. Name and Address of Reporting Person* Samuel George A. III						2. Issuer Name and Ticker or Trading Symbol Lineage Cell Therapeutics, Inc. [ LCTX ]								(Check all applicable) Director	Officer (give title	5. Relationship of Reporting Person(s) to Issuer 10% Owner Other (specify
(Last)	(First) C/O LINEAGE CELL THERAPEUTICS 2173 SALK AVENUE, SUITE 200	3. Date of Earliest Transaction (Month/Day/Year) 09/01/2021									X below) below) General Counsel/Secretary
(Street) CARLSBAD CA 92008 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)							Line) X	6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person
						Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
2. Transaction 1. Title of Security (Instr. 3) Date (Month/Day/Year)					2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
										Code V Amount		(D)	Price	(Instr. 3 and 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed 4. Execution Date, if any		Transaction Code (Instr.	5. Number of Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying		8. Price of Derivative Security	9. Number of derivative Securities		10. Ownership Form:	11. Nature of Indirect Beneficial

						3, 4 and 5)							Reported Transaction(s)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)
Employee Stock Option (right to buy)	\$2.55	09/01/2021		A		695,000		(1)	09/01/2031 Common	Shares	695,000	\$0.00	695,000	D

Acquired (A) or Disposed of (D) (Instr.

Explanation of Responses:

Price of Derivative Security

(Instr. 3)

1. This option will vest as to one quarter of the shares subject to the option on September 1, 2022, and the balance will vest in 36 successive substantially equal monthly installments thereafter, subject to the reporting person's continuous employment.

/s/ Grant Harbert, as Attorneyin-Fact 09/02/2021

(Instr. 5)

Beneficially Owned Following

Direct (D) or Indirect (I) (Instr. 4) Ownership (Instr. 4)

Derivative Security (Instr. 3 and 4)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Month/Day/Year)

8)

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.